X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Featured

AstraZeneca Cites Early Lung Cancer Immunotherapy Success

Content Team by Content Team
4th July 2022
in Featured, Manufacturing, Middle East and South Asia, News
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

The most prevalent kind of the disease, non-small cell lung cancer, has seen steady advancements in immunotherapies called checkpoint inhibitors during the past ten years. First, medications like Keytruda from Merck & Co., Opdivo from Bristol-Myers Squibb, and Tecentriq from Roche have become standard therapies for patients with metastatic disease. They are now more frequently made available this year, either before or after tumour removal operations.

For patients with primary lung cancer, the FDA has approved medication combinations comprising Opdivo and Tecentriq since January. Merck has stated that it intends to submit an application for Keytruda after disclosing the results of Phase 3 research in March. Imfinzi from AstraZeneca may soon join them after its launch, though it is still unclear how the medication stacks up against its rivals. Pathological full responses are a proxy for more meaningful outcomes, such as extending survival or slowing the spread of cancer, and the research hasn’t been running long enough to see how the medicine fared on those metrics.

When those figures are made public, it will be possible to determine whether immunotherapy for tumours has a greater impact than tumour removal procedures. Opdivo plus chemotherapy was examined for a brief nine-week period prior to surgery by Bristol Myers, who found a 37% decrease in the chance of relapse or mortality across the board. Following surgery, Roche and Merck investigated extended medication regimens. In the end, Roche achieved a risk reduction of 21% across the board and better outcomes with a 34% decrease in patients whose tumours express at least some of the protein PD-L1, which is linked to better therapeutic efficacy. Merck reported a risk reduction of 24% overall but a smaller average reduction of 18% in those with high PD-L1 levels. How long they can lengthen life has never been established with certainty. Research is continuing.

In contrast, AstraZeneca studied a 12-week regimen of Imfinzi and chemotherapy prior to surgery that was followed by up to 12 treatment cycles. Details of the study will be presented at a subsequent medical conference. While this is going on, Roche is also conducting a Phase 3 trial to evaluate a Tecentriq regimen that starts before surgery and continues after.

 A Snapshot

  • The British pharmaceutical company reported on June 30th that Imfinzi, an immunotherapy from AstraZeneca, helped patients with early non-small cell lung cancer achieve the first of two major study objectives.
  • After conducting a preliminary analysis, the study researchers discovered that patients who received chemotherapy and Imfinzi beginning before and trying to continue after surgical removal of a tumour demonstrated highly significant and constructive improvement compared to those receiving only chemotherapy in terms of what are known as pathological complete responses, or the absence of tumour cells on a scan. AstraZeneca withheld further information.
  • The AEGEAN research will continue to examine how well the medicine mixture prevents cancer from returning, which is also one of its primary goals and a metric other businesses have used to justify authorization in early lung cancer. AstraZeneca will nonetheless communicate its findings with international health authorities in the interim.

Previous Post

FDA Experts Recommend Changing COVID Jab Formulation In Fall

Next Post

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In